Intracoronary thrombus in a 26-year-old man.

Walter U, Bauersachs J. Inhibition of platelet activation in congestive heart failure by aldosterone. Thromb Haemost 2003;89:1024–1030. 62. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86. 63. Cleland JGF, Ghosh J, Freemantle N, Kaye GC, Nasir M, Clark AL, Coletta AP. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-LIPIDS and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004;6:501–508. 64. Guazzi M, Brambilla R, Reina G, Tumminello G, Guazzi MD. Aspirin-angiotensin-convering enzyme inhibitor coadministration and mortality in patients with heart failure: a dose-related adverse effect of aspirin. Arch Intern Med 2003;163:1574–1579. 65. Kindsvater S, Leclerc K, Ward J. Effects of coadministration of aspirin or clopidogrel on exercise testing in patients with heart failure receiving angiotensin-converting enzyme inhibitors. Am J Cardiol 2003;91: 1350–1352. 66. Serebruany VL, Malinin AI, Jerome SD, Lowry DR, Morgan AW, Sane DC, Tanguay JF, Steinhubl SR, O’connor CM. Effects of clopidgrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Am Heart J 2003;146:713–720. 67. Srichai MB, Jaber WA, Prior DL, Marso SP, Houghtaling PL, Menon V, Simoons ML, Harrington RA, Hochman JS, PURSUIT Investigators. Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes. Am Heart J 2004;147:84–90. 68. Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK, HELAS investigators. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 2006;8:428–432. 69. Lip GYH, Chung I. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm. Cochrane Database Syst Rev 2000 doi:10.1002/14651858.CD003333. 70. Lip GYH, Chung I. Anticoagulation for heart failure in sinus rhythm. Cochrane Database Syst Rev 2000 doi:10.1002/14651858.CD003336. 71. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, Gibson CM, Cannon CP, Braunwald E, Schonbeck U. Soluble CD40L risk prediction after acute coronary syndrome. Circulation 2003;108:1049–1052. 72. Chin BS, Blann AD, Gibbs CR, Chung NAY, Conway DS, Lip GY. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest 2003;33:941–948.